Document is current

Article History

Received: 17 February 2025

Revised: 17 April 2025

Accepted: 28 April 2025

First Online: 29 May 2025

Competing interests

: CK is CEO of LikGevity. BD is Head of R&D of LinkGevity and formerly held senior leadership positions, inc. director of scientific operations, at GlaxoSmithKline (GSK). JB holds equity in LinkGevity; is Director of Health Sciences and Technology at Massachusetts General Hospital, Harvard, USA; Chair of Renal Medicine, Harvard; Chief, Renal Division; Chief, Division of Engineering in Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard; Past President, American Society of Nephrology; and Member of the Kidney Cancer Program at the Dana-Farber/Harvard Cancer Center. ER is Managing Director, Starburst Aerospace, USA and Director of NASA Human Research Program, Microsoft and Translational Research Institute Space-Health (Space-H) Program, USA. NG is CTO at LinkGevity. HK is a LIDO student at LinkGevity. DMB is Editor-in-Chief of Experimental Physiology; Chair of the Life Sciences Working Group, European Space Agency; Member of the Human Spaceflight and Exploration Science Advisory Committee to the European Space Agency; Member of the Space Exploration Advisory Committee to the UK and Swedish National Space Agencies; and Member of the National Cardiovascular Network for Wales and South-East Wales Vascular Network. DMB is also affiliated to Bexorg, Inc. (USA) focused on the technological development of novel biomarkers of cerebral bioenergetic function and structural damage in humans.